Clinical Trials Browser

Withdrawn × INDUSTRY × cemiplimab × Clear all

NCT04373083 2021-01-15

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Phase 2 Withdrawn

Hodgkin Disease

NCT02520245 2016-11-07

Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study

Phase 1 Withdrawn

Advanced Malignancies